PL1831402T3 - Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę - Google Patents

Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę

Info

Publication number
PL1831402T3
PL1831402T3 PL05855433T PL05855433T PL1831402T3 PL 1831402 T3 PL1831402 T3 PL 1831402T3 PL 05855433 T PL05855433 T PL 05855433T PL 05855433 T PL05855433 T PL 05855433T PL 1831402 T3 PL1831402 T3 PL 1831402T3
Authority
PL
Poland
Prior art keywords
vkorc1
genetic variants
polymorphism
warfarin sensitivity
warfarin
Prior art date
Application number
PL05855433T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Hsiang-Yu Yuan
Jin-Jer Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1831402(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of PL1831402T3 publication Critical patent/PL1831402T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL05855433T 2004-12-21 2005-12-21 Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę PL1831402T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63883704P 2004-12-21 2004-12-21
US67969405P 2005-05-10 2005-05-10
EP05855433A EP1831402B1 (en) 2004-12-21 2005-12-21 Genetic variants of vkorc1 predicting warfarin sensitivity
PCT/US2005/046869 WO2006069339A2 (en) 2004-12-21 2005-12-21 Genetic variants of vkorci predicting warfarin sensitivity

Publications (1)

Publication Number Publication Date
PL1831402T3 true PL1831402T3 (pl) 2010-12-31

Family

ID=36602356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05855433T PL1831402T3 (pl) 2004-12-21 2005-12-21 Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę

Country Status (19)

Country Link
US (2) US20060166239A1 (pl)
EP (2) EP2246445A1 (pl)
JP (1) JP4516990B2 (pl)
KR (1) KR101178463B1 (pl)
CN (1) CN101142322B (pl)
AT (1) ATE470725T1 (pl)
AU (1) AU2005319028B2 (pl)
BR (1) BRPI0519570A2 (pl)
CA (1) CA2591840C (pl)
DE (1) DE602005021821D1 (pl)
DK (1) DK1831402T3 (pl)
ES (1) ES2347167T3 (pl)
HK (1) HK1117571A1 (pl)
MX (1) MX2007007568A (pl)
NZ (1) NZ556461A (pl)
PL (1) PL1831402T3 (pl)
PT (1) PT1831402E (pl)
TW (1) TWI334886B (pl)
WO (1) WO2006069339A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
ES2575903T3 (es) 2003-02-20 2016-07-04 Mayo Foundation For Medical Education And Research Métodos para seleccionar medicamentos antidepresivos
PL1842920T5 (pl) * 2003-09-23 2018-04-30 University Of North Carolina At Chapel Hill Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
AU2005329450A1 (en) * 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
ES2529211T3 (es) * 2005-11-29 2015-02-18 Children's Hospital Medical Center Optimización e individualización de la selección y dosificación de medicamentos
US8380539B2 (en) * 2006-05-09 2013-02-19 University Of Louisville Research Foundation, Inc. Personalized medicine management software
US8039212B2 (en) * 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
ES2927105T3 (es) * 2008-10-20 2022-11-02 Epitome Pharmaceuticals Ltd Métodos y sistemas para mejorar la intervención farmacéutica en el control de la coagulación
KR101157135B1 (ko) * 2008-12-29 2012-06-18 인제대학교 산학협력단 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법
EP2233580A1 (en) * 2009-03-05 2010-09-29 The Ohio State University Rapid genotyping of SNPs
JP5843487B2 (ja) 2010-06-01 2016-01-13 アークレイ株式会社 Vkorc1遺伝子の−1639番目の塩基の多型検出法、ならびにそのための核酸プローブおよびキット
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
TWI564392B (zh) * 2012-08-21 2017-01-01 財團法人工業技術研究院 偵測生物材料的系統及方法
CN103173443B (zh) * 2013-03-22 2016-08-24 卫生部北京医院 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用
CA3049961A1 (en) 2016-12-09 2018-06-14 The Broad Institute, Inc. Crispr effector system based diagnostics
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
AU2018265421B2 (en) * 2017-05-12 2024-03-07 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
BR112020015093A2 (pt) 2018-01-29 2020-12-08 The Broad Institute, Inc. Diagnóstico baseado no sistema de efetor crispr
US20220220546A1 (en) 2019-03-14 2022-07-14 The Broad Institute, Inc. Sherlock assays for tick-borne diseases
CN110592206A (zh) * 2019-09-11 2019-12-20 上海交通大学 一种利用rs9934438检测华法药效的试剂盒
KR102506347B1 (ko) 2021-05-11 2023-03-03 충북대학교 산학협력단 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
PL1842920T5 (pl) * 2003-09-23 2018-04-30 University Of North Carolina At Chapel Hill Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K
KR20070085406A (ko) * 2004-10-18 2007-08-27 유니버시티 오브 워싱톤 약물 반응성을 예측하기 위한 방법 및 조성물
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
US20080005732A1 (en) * 2006-05-11 2008-01-03 Coon Robert F Method and System for Integrating Software Update Services with Software Applications

Also Published As

Publication number Publication date
MX2007007568A (es) 2008-03-11
AU2005319028B2 (en) 2010-09-16
TW200637918A (en) 2006-11-01
WO2006069339A8 (en) 2010-06-03
EP2246445A1 (en) 2010-11-03
CA2591840A1 (en) 2006-06-29
EP1831402B1 (en) 2010-06-09
KR101178463B1 (ko) 2012-09-07
ES2347167T3 (es) 2010-10-26
BRPI0519570A2 (pt) 2009-01-27
DE602005021821D1 (de) 2010-07-22
ATE470725T1 (de) 2010-06-15
TWI334886B (en) 2010-12-21
US20060166239A1 (en) 2006-07-27
PT1831402E (pt) 2010-09-10
AU2005319028A1 (en) 2006-06-29
CN101142322A (zh) 2008-03-12
DK1831402T3 (da) 2010-09-20
EP1831402A2 (en) 2007-09-12
WO2006069339A3 (en) 2006-10-12
NZ556461A (en) 2009-12-24
US20110236885A1 (en) 2011-09-29
CN101142322B (zh) 2011-09-21
CA2591840C (en) 2012-07-10
KR20080005179A (ko) 2008-01-10
JP4516990B2 (ja) 2010-08-04
HK1117571A1 (en) 2009-01-16
JP2008523844A (ja) 2008-07-10
WO2006069339A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
PL1831402T3 (pl) Genetyczne warianty VKORC1 przewidujące wrażliwość na warfarynę
HK1105437A1 (en) Methods and compositions for predicting response to warfarin
IL225203A (en) An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity
DK1842920T3 (da) Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
DE602005009702D1 (de) Esr1 und gebärmutterhalskrebs
WO2008048119A3 (en) Methods of analysis of polymorphisms and uses thereof
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
ZA200710910B (en) Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
EA201171171A1 (ru) Генетические маркеры степени тяжести рассеянного склероза
PT1529116E (pt) Métodos para o tratamento da demência com base no genótipo da apo e
ATE540966T1 (de) Von phenoxazinon abgeleitete neue enzymsubstrate und deren verwendung als entwickler bei der detektion von mikroorganismen mit peptidaseaktivität
WO2008048902A8 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
ATE489483T1 (de) Assoziation von pde4d-allelvarianten mit schlaganfall
EP1829979A4 (en) GENE IDENTIFICATION METHOD WITH VARIABLE EXPRESSION
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis
TW200510546A (en) Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus
WO2005108624A3 (en) Use of hla-g genotyping in immune-mediated conditions
DE602004021366D1 (pl)
ATE395437T1 (de) Mit vorzeitiger canities in verbindung gebrachte polymorphismen von chromosom 9
PT1673472E (pt) Utiliza??o de polimorfismos gen?ticos na predi??o de hepatotoxicidade induzida por f?rmacos
WO2007110869A3 (en) Methods and kits for determining predisposition to warfarin resistance
WO2007044433A3 (en) Genetic polymorphisms predictive of nutritional requirements for choline in subjects
JP2008520230A5 (pl)